Literature DB >> 12567198

Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations?

U Nowak-Göttl1, C Escuriola, K Kurnik, R Schobess, S Horneff, A Kosch, W Kreuz, H Pollmann.   

Abstract

UNLABELLED: For the study presented here 135 pediatric PUP patients with haemophilia consecutively admitted to German pediatric haemophilia treatment centers were investigated. In addition to factor VIII activity, the factor V (FV) G1691A mutation, the factor II (FII) G20210A variant, methylenetetrahydrofolate reductase (MTHFR) T677T genotype, elevated lipoprotein a (Lp a), antithrombin, protein C, and protein S were investigated. 103 out of 122 HA patients (FVIII activity <1%) were suffering from severe HA. The prevalence of prothrombotic risk factors in children with severe haemophilia A (HA) did not differ from previously reported data: FV GA 5.8%, FII GA 3.9%, MTHFR TT 10%, elevated Lp a 7%, protein C type I deficiency 1.1%. The first symptomatic bleeding leading to diagnosis of severe haemophilia occurred with a median age of 1.6 years (range: 0.5-7.1 years) in children carrying prothrombotic risk factors compared to non-carriers (0.9 years (0.1-4.0; p = 0.01). Two patients presenting with neonatal stroke due to elevated Lp a and the FII GA variant showed haemorrhagic stroke transformation triggered by severe haemophilia. In addition, when haemophilia A was corrected by administration of factor VIII concentrates eight out of 25 children with central lines in place developed catheter-related thrombosis.
CONCLUSION: The data of this multicentre cohort study demonstrate that the clinical phenotype of severe haemophilia A in childhood is clearly influenced by the coinheritance of prothrombotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12567198

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  7 in total

Review 1.  Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

Authors:  A Girolami; F Tezza; M Scapin; S Vettore; A Casonato
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

Review 2.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

Review 3.  Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases.

Authors:  Antonio Girolami; Raffaella Scandellari; Ezio Zanon; Roberto Sartori; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 4.  Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases.

Authors:  A Girolami; M L Randi; E Ruzzon; E Zanon; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

5.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

Review 6.  Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.

Authors:  Kim Fechtel; Marika L Osterbur; Hildegard Kehrer-Sawatzki; Peter D Stenson; David N Cooper
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

7.  Genetic biomarkers related to hemarthrosis, inflammation, and cartilage structure in pediatric patients with hemophilic arthropathy.

Authors:  José de Jesús López-Jiménez; Ricardo Ortega-Cervantes; Hilda Luna-Záizar; Ana-Lilia Fletes-Rayas; Claudia-Patricia Beltrán-Miranda; Rogelio Troyo-Sanromán; Janet Soto-Padilla; Alberto Tlacuilo-Parra; Ana-Rebeca Jaloma-Cruz
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.